|Oral, intramuscular injection|
|Synonyms||Testosterone hexadecanoate; Testosterone 17β-palmitate; Androst-4-en-17β-ol-3-one 17β-palmitate|
|Chemical and physical data|
|Molar mass||526.846 g/mol|
|3D model (Jmol)||Interactive image|
Testosterone palmitate, or testosterone hexadecanoate, also known as testosterone 17β-palmitate, as well as androst-4-en-17β-ol-3-one 17β-palmitate, is an anabolic-androgenic steroid (AAS) and an androgen ester – specifically, the C17β palmitate (hexadecanoate) ester of testosterone – which was never marketed. It is a prodrug of testosterone and, when administered via intramuscular injection, is associated with a long-lasting depot effect and extended duration of action.
Testosterone palmitate is a longer-chain ester of testosterone compared to testosterone undecanoate. Relative to testosterone undecanoate, testosterone palmitate shows higher oral bioavailability. However, no free testosterone was observed after administration of testosterone palmitate, suggesting that it is not hydrolyzed as well. On the other hand, another study found that testosterone palmitate was hydrolyzed in humans.
- Elka Touitou; Brian W. Barry (27 November 2006). Enhancement in Drug Delivery. CRC Press. pp. 122–. ISBN 978-1-4200-0481-6.
- Edith Josephy; F. Radt (1 December 2013). Elsevier’s Encyclopaedia of Organic Chemistry: Series III: Carboisocyclic Condensed Compounds. Springer. pp. 3048–. ISBN 978-3-662-25863-7.
- United States. Environmental Protection Agency. Office of Toxic Substances (1977). Toxic Substances Control Act (TSCA): PL 94-469 : Candidate List of Chemical Substances. Environmental Protection Agency, Office of Toxic Substances. pp. 315–.
- Dissertation Abstracts International: The sciences and engineering. University Microfilms. 1990. p. 4857.